Thomas A. Hope
Nuclear medicine physician who led the trials that got PSMA PET approved in the United States.
Overview
Thomas Hope is Professor of Radiology and Chief of Nuclear Medicine at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center. A nuclear medicine physician specialising in PSMA PET and theranostics, his prospective studies of 68Ga-PSMA-11 PET at UCSF and UCLA supported the first FDA approval of PSMA PET in the United States in 2020. His papers include a JAMA Oncology multicentre prospective phase 3 imaging trial of the diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis before radical prostatectomy and a JAMA Oncology prospective single-arm trial assessing its accuracy in localising recurrent prostate cancer. He leads theranostics research and PSMA radioligand dosimetry work in prostate cancer.
Similar pages
not linked directly; found by shared links- PersonRahul Aggarwal
Shares UCSF Helen Diller Family Comprehensive Cancer Center, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares PET (positron emission tomography), PSMA, PSMA PET, Gallium-68.
- TrialPSMA-PET to Guide Prostatectomy
Shares PET (positron emission tomography), PSMA, Prostate cancer.
- AgentPSMA-1007 F-18
Shares PET (positron emission tomography), PSMA, PSMA PET, Gallium-68.
- AgentCholine C-11
Shares PET (positron emission tomography), PSMA PET, Gallium-68, Prostate cancer.
- PersonPeter Bartenstein
Shares PSMA, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- PersonJeremie Calais
Shares PSMA, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- TrialInvestigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Shares PET (positron emission tomography), Gallium-68, Prostate cancer.